
|Videos|December 2, 2014
The Utility of Cabazitaxel
Author(s)William K. Oh, MD
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.
Advertisement
Clinical Pearls
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.
- Cabazitaxel was approved several years ago for patients with prostate cancer who progress on docetaxel.
- Chemotherapy has a clear benefit in treating prostate cancer.
- The CHAARTED study will likely change the way cabazitaxel is used in practice.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































